Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMC plus methotrexate in HRD-positive, treatment-resistant metastatic breast cancer
jRCTs031250811Recruiting
- Start
- Mar 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of mitomycin c and methotrexate in breast cancer. Primary endpoint: Objective Response Rate. Started Mar 2026; status: recruiting.
02
Drugs
mitomycin cmethotrexate
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCTs031250811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250811.